source
- Oak Hill takes SPAC track to Nasdaq with Roche asset in towOak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.
- Webinar Explores AI-Driven Intelligence Engine for Optimizing Antibody, ADC and Peptide CandidatesDrug discovery teams are grappling with an ever‑growing volume of data, and converting that data into actionable insight remains a key hurdle. In a recent BioSpace webinar, Patsnap’s Ben Coverdale…